Automated ERCC1 immunohistochemistry in non-small cell lung cancer: Comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 2, 2011, Pages 99-105

  Arbogast, Stefanie ^a   Behnke, Silvia ^a   Opitz, Isabelle ^b   Stahel, Rolf A ^c   Seifert, Burkhardt ^d   Weder, Walter ^b   Moch, Holger ^a   Soltermann, Alex ^a  

^a Institute for Surgical Pathology   (Switzerland)

^b Division of Thoracic Surgery   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

ERCC1; immunohistochemistry; Non small cell lung cancer; nucleotide excision repair; tissue microarray

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FORMALDEHYDE; POLYCLONAL ANTIBODY; PROTEIN; PROTEIN ANTIBODY;

ADENOCARCINOMA; ADULT; ARTICLE; AUTOMATION; CANCER SIZE; CANCER STAGING; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL NUCLEUS; COMPARATIVE STUDY; CYTOPLASM; FEMALE; GOBLET CELL; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEOLUS; OVERALL SURVIVAL; PATHOLOGIST; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM; STAINING; TISSUE MICROARRAY;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; AUTOMATION, LABORATORY; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RABBITS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79951952721     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181f1feeb     Document Type: Article

References (20)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98. (Pubitemid 34438899)
2. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016-3024. (Pubitemid 46606280)
3. de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13:768-785. (Pubitemid 29169836)
4. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22-33. (Pubitemid 33741878)
5. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14:1291-1295. (Pubitemid 351413906)
6. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991. (Pubitemid 44343542)
7. Soria JC. ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. J Clin Oncol. 2007;25:2648-2649.
8. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33:565-577. (Pubitemid 47355341)
9. Booton R, Ward T, Ashcroft L, et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:902-906. (Pubitemid 47511592)
10. Olaussen KA, Fouret P, Kroemer G. ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl JMed. 2007;357:1559-1561. (Pubitemid 47572656)
11. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800-808. (Pubitemid 46294612)
12. Lee HW, Han JH, Kim JH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer. 2008; 59:95-104.
13. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504-509. (Pubitemid 46359630)
14. Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-smallcell lung cancer. N Engl J Med. 2007;356:2538-2540.
15. Bhagwat NR, Roginskaya VY, Acquafondata MB, et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009;69:6831-6838.
16. Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol. 2009;22:1032-1043.
17. Soltermann A, Tischler V, Arbogast S, et al. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res. 2008;14:7430-7437.
18. Camenisch U, Trautlein D, Clement FC, et al. Two-stage dynamic DNA quality check by xeroderma pigmentosum group C protein. Embo J. 2009;28:2387-2399.
19. Cummings M, Higginbottom K, McGurk CJ, et al. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol. 2006;72:166-175. (Pubitemid 43870167)
20. Holm B, Mellemgaard A, Skov T, et al. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27: 4254-4259.